Deerfield Management Company, L.P. (Series C) Larimar Therapeutics, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 21,231,974 shares of LRMR stock, worth $139 Million. This represents 3.23% of its overall portfolio holdings.
Number of Shares
21,231,974
Previous 21,231,974
-0.0%
Holding current value
$139 Million
Previous $161 Million
4.48%
% of portfolio
3.23%
Previous 3.33%
Shares
4 transactions
Others Institutions Holding LRMR
# of Institutions
111Shares Held
68MCall Options Held
290KPut Options Held
38.9K-
Ra Capital Management, L.P. Boston, MA6.05MShares$39.7 Million0.66% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$28.8 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.33MShares$28.5 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.86MShares$25.4 Million11.62% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$22.4 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $284M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...